Most of us are fairly adept by now at managing COVID-19, with an armor of previous infections, vaccinations, self-tests, and antiviral medicines like Paxlovid.
Within the newest research, nonetheless, researchers report that taking Paxlovid could not present as a lot profit as docs initially thought—significantly for older people who find themselves vaccinated.
In a analysis letter printed in JAMA on Feb. 20, Dr. John Mafi, affiliate professor of medication on the David Geffen Faculty of Drugs at UCLA, and his colleagues used Canadian knowledge to discover what occurred when folks took Paxlovid. A Canadian well being coverage in 2022 allowed prescriptions for Paxlovid just for symptomatic folks round age 70 with a view to reserve the treatment for many who wanted it most. Older individuals are at greater danger of creating issues from COVID-19. The coverage allowed the scientists to match folks on this age group who took Paxlovid to those that didn’t.
Among the many almost 1.5 million folks they studied, those that obtained prescriptions for the drug didn’t have considerably completely different charges of being hospitalized or dying from COVID-19 than those that didn’t get the drug. The general public studied had been vaccinated.
“Our important discovering was that amongst vaccinated older adults, Paxlovid confirmed no statistically important discount in COVID-19 hospitalizations or on mortality,” says Mafi, the research’s lead creator.
That’s very completely different from the outcomes that Paxlovid’s maker, Pfizer, first reported in 2022. In that research, Pfizer discovered that the drug decreased hospitalizations and deaths from COVID-19 by 89% in comparison with folks receiving placebo. However the group they studied was largely middle-aged and unvaccinated, which is a a lot completely different inhabitants than exists at present. “But that 2022 Pfizer research was and continues for use to assist the idea that the advantages of Paxlovid in unvaccinated adults additionally apply to vaccinated adults,” says Mafi. “That’s what’s getting used to justify its perceived effectiveness—and its listing value at $1,650 per therapy course.”
In an announcement, Pfizer mentioned it couldn’t touch upon a research wherein it didn’t take part, however that the corporate “stay[s] assured in Paxlovid’s medical effectiveness at stopping extreme outcomes, together with hospitalization and demise, from COVID-19 in sufferers at excessive danger of extreme sickness.”
Learn Extra: Lengthy COVID Doesn’t All the time Look Like You Suppose It Does
Paxlovid is supposed to assist these at excessive danger of creating issues from COVID-19, together with the aged, folks with compromised immune programs, and people with a number of underlying well being situations. That continues to be a main criterion for prescribing the treatment, which is now out there for anybody age 12 or older and who’s at excessive danger of extreme illness.
Nonetheless, Mafi says there aren’t robust knowledge on how Paxlovid impacts the illness course in people who find themselves vaccinated. His findings recommend that the advantages are about 4 instances smaller than these reported by Pfizer.
“We aren’t saying that Paxlovid is ineffective,” says Mafi. “What this analysis is saying is that its effectiveness in older teams who’re most susceptible to COVID-19, however who’re vaccinated, is much decrease than what the sooner proof from unvaccinated teams confirmed.”
Extra analysis is required, however docs can contemplate this new data when deciding whether or not to advocate a affected person take Paxlovid. Different vital elements embrace an individual’s medical historical past, the treatment’s danger of comparatively delicate negative effects, and Paxlovid rebound, wherein folks taking Paxlovid could check constructive once more after testing unfavorable.
Dr. Katherine Kahn, distinguished professor of medication at UCLA and the research’s senior creator, says that she’s going to talk about the newest outcomes along with her sufferers, and “for usually well being folks, I’m not encouraging or discouraging [Paxlovid] in the event that they meet the factors for taking it,” she says. “However for folks with greater danger of morbidity or mortality, we’re extra prone to say we would contemplate [Paxlovid] at the moment, although we don’t know 100% if you’ll profit.”
The brand new research raises questions for future analysis. It doesn’t bear in mind, as an example, how previous infections would possibly trigger the physique to reply to Paxlovid. Mafi and Kahn say that they had been additionally not in a position to delve extra deeply into individuals’ vaccination historical past—what number of and which doses they obtained—or verify whether or not they took Paxlovid inside 5 days of their first signs, when the drug is best. However they’re planning to entry the individual-level knowledge and do a extra in-depth evaluation of different elements that will impression how efficient the drug is at lowering hospitalizations and deaths.
“One of many conclusions of this research is the advice for extra research, of each older people and people who are vaccinated, of the effectiveness of Paxlovid,” says Kahn.